Autres langues Torii Pharmaceutical Co., Ltd.

Actions

4551

JP3635800000

Temps Différé Japan Exchange Autres places de cotation 08:00:00 18/07/2024			Varia. 5j.	Varia. 1 janv.
3 750 ^JPY	0,00 %		+0,54 %	+5,49 %

15/05	Verrica Pharmaceuticals modifie son accord de licence avec Torii Pharmaceutical pour l'essai de phase 3 d'Ycanth	MT
15/05	Verrica Pharmaceuticals Inc. annonce la modification de l'accord de collaboration et de licence avec Torii Pharmaceutical Co. Ltd. pour financer un essai clinique pivot de phase 3 à l'échelle mondiale afin d'étudier Ycanth pour le traitement des verrues communes	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Torii Pharmaceutical : JT Receives Manufacturing and Marketing Approval of VTAMA® Cream 1% for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	24/06
Torii Pharmaceutical : Positive Top line Results of Phase 3 Clinical Study (Comparative Study) of JTE 061 (tapinarof) Cream, Aryl hydrocarbon Receptor (AhR) agonist, in Pediatric Patients with Atopic Dermatitis in Japan	31/05
Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	15/05
Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	15/05
Torii Pharmaceutical Co., Ltd Announces Voting Results	29/03
LIM Advisors Partially Withdraws Shareholder Proposal	13/02
Torii Pharmaceuticals Opposes Shareholder Proposal	09/02
Torii Pharmaceutical - Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	18/12
Verrica Pharmaceuticals Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208	18/12
Verrica Pharmaceuticals' Partner Reports Positive Data From Phase 3 Trial of Skin Infection Treatment	15/12
Torii Pharmaceutical : Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	15/12
Torii Pharmaceutical Co., Ltd. Announces Positive Top-Line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan	15/12
Torii Pharmaceutical : Signing of an Agreement for the Exclusive Development and Commercialization of GRAZAX®,an Allergen Immunotherapy (Sublingual Immunotherapy) Drug for Grass Pollinosis in Japan	13/12
ALK Abello Adds Grass Pollen Allergy Drug to Torii License Deal in Japan	12/12
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	12/12
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise	30/11
Torii Pharmaceutical : Financial Results for the First Nine Months of Fiscal Year Ending December 2023	31/10/23
Torii Pharmaceutical - JT Files New Drug Application of JTE-061 Cream, Aryl hydrocarbon Receptor agonist, for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	18/09/23
Torii Pharmaceutical : JT Files New Drug Application of JTE-061 Cream,Aryl hydrocarbon Receptor (AhR) agonist,for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	15/09/23
Torii Pharmaceutical : Financial Results for the First Three Months of Fiscal Year Ending December 2023	28/04/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Torii Pharmaceutical Co., Ltd.

Actions

4551

JP3635800000

Autres langues

Filtres